Inovio Pharmaceuticals, Inc. Press Releases

INO 
$9.75
*  
0.35
3.47%
Get INO Alerts
*Delayed - data as of Aug. 1, 2014  -  Find a broker to begin trading INO now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
8/1/2014 8:00:00 AM - PR Newswire

Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
7/23/2014 9:15:00 AM - PR Newswire

Inovio Pharmaceuticals Added To Russell Global, Russell 2000® and Russell Microcap® Indexes
7/1/2014 4:00:00 AM - PR Newswire

Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma
6/26/2014 7:10:00 AM - PR Newswire

Inovio Pharmaceuticals Initiates Cervical Cancer Clinical Trial
6/23/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals Broadens its Intellectual Property Portfolio from the University of Pennsylvania
6/17/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals to Present at Upcoming Healthcare Conferences
6/16/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
6/11/2014 9:00:00 AM - PR Newswire

Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV
6/10/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals Announces Reverse Stock Split Date
5/30/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals Subsidiary Sells Animal Health Assets
5/27/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals Breakthrough DNA-Based Monoclonal Antibody Therapy Completely Protects Animals From Lethal Viral Challenge
5/27/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
5/23/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference
5/21/2014 4:00:00 AM - PR Newswire

Pre-Market Pulse on Top Gainers -- Research on Inovio Pharma, Novavax, FreeSeas, and ImmunoCellular Therapeutics
5/20/2014 11:05:00 AM - PR Newswire

Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis
5/13/2014 4:00:00 AM - PR Newswire

Inovio Pharmaceuticals Reports 2014 First Quarter Financial Results
5/12/2014 6:10:00 AM - PR Newswire

Inovio Pharmaceuticals to Report First Quarter 2014 Financial Results on May 12, 2014
5/5/2014 4:00:00 AM - PR Newswire